Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

Siefker-Radtke, A. O.Loriot, Y.Siena, S.Beato, C.Climent Duran, M. A.Varlamov, S.Duran, I.Tagawa, S. T.Geoffrois, L.Mellado, B.Semenov, A.Delva, R.Lykov, A. P.Dirix, L. Y.Akapame, S.O'Hagan, A.Tammaro, M.Mosher, S.Kang, T. W.Moreno, V.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27557enUpdated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterationsconference outputopen access10.1016/j.annonc.2020.08.8241569-8041http://www.annalsofoncology.org/article/S0923753420408208/pdf573469101040